I graduated from Cambridge University in 1995 and completed both my junior medical training and my oncology specialist training in Oxford.
I am principal investigator for clinical trials in lung and breast cancer at the Royal Berkshire Hospital, Reading. I also refer patients for clinical trials where appropriate (including the Royal Marsden and University College Hospital, London).
Clinical Governance Lead in the Berkshire Cancer Centre, Royal Berkshire Hospital, Reading 2006-2011.
Clinical lead for Chemotherapy in the Berkshire Cancer Centre, Royal Berkshire Hospital, Reading 2011-2017.
Clinical Supervisor for specialist oncology trainees.
Addition of Apatorsen, an inhibitor of Hsp27, to first-line gemcitabine/carboplatin in advanced squamous cell lung cancer: Design of the Cedar study. ASCO 2016.
A Phase II, randomised, open-label study of Gemcitabine/Carboplatin first-line chemotherapy in combination with or without the antisense oligonucleotide Apatorsen (OGX-427) in advanced squamous cell lung cancers ESMO 2017.
I have also written chapters for the Oxford Handbook of Emergencies in Oncology, and Problem solving in Oncology.
2014: Cycled from Reading to Barcelona on a tandem with Nurse Consultant Mark Foulkes on a charity cycle ride to raise funds to facilitate the local delivery of chemotherapy for patients in West Berkshire.
2017 Nominated for National Oncology Registrars’ Forum Trainer Award.
I am fully registered with the GMC (4259509) and hold a certificate of completion of specialist training in Clinical Oncology.
I have accepted educational grants to fund attendance at both national and international cancer conferences. I have provided training and updates for pharmaceutical companies when requested. I have no financial interests in any pharmaceutical company.
I am an investor in the Genesis Care,Windsor, Diagnostic and Oncology Centre.